-
Americans are not signing up for consumer-driven health plans (CDHP) that offer reduced premiums with higher deductibles of $1,000 or more for employee-only coverage and $2,000 or more for family coverage, according to a recent survey by the Employee Benefit Research Institute (EBRI) and The Commonwealth Fund.
-
Patients who recently were hospitalized but who may not be eligible for disease management or care management programs get support in complying with their post-discharge instructions through a care management followup program by BlueCross BlueShield of Minnesota.
-
A team of behavioral health case managers and disease management case managers work together to manage the care for members with chronic diseases and depression at Health Alliance Plan.
-
For many years, many people thought of depression as an imaginary disease, but the health care industry is beginning to recognize how prevalent depression really is and is taking steps to help people learn to cope with this devastating disease.
-
Members who seek treatment for depression and anxiety from a primary care physician are getting help managing their condition through a new program from CIGNA HealthCare.
-
Nurses or physicians who place patients in restraints or in isolation now must meet stricter training and documentation requirements thanks to a strengthened federal patient's rights rule effective as of Feb. 6.
-
Communication between health care providers and the families of critically ill and dying children is simultaneously the most important and most difficult task in some cases.
-
Parents of children who died in pediatric intensive care units want doctors and nurses to know that they respect and appreciate care providers' technical skills, but what they need more of is a personal, emotional connection with their children's medical providers.
-
Are research and quality improvement (QI) mutually exclusive, or natural partners? When QI crosses over into research, what ethical issues can arise?
-
The number of academic medical centers that are banning free drug samples, free lunches, and other gifts from pharmaceutical company representatives remains small, but continues to grow.